6667.HK Mega Genomics pre-market up 5.03% on volume spike: Watch 73.52x volume (HKSE)

We see a clear pre-market volume spike in 6667.HK stock on 10 Mar 2026, with the price at HK$7.31 and a +5.03% move. Volume is 3,400 versus an average of 389, a 73.52x surge that flags active order flow ahead of the Hong Kong open. The intraday range opened at HK$6.98 and hit HK$7.31 so far, up from a previous close of HK$6.96. This move is notable because technical momentum and cash flow metrics diverge from valuation measures. We outline why the volume spike matters, what the charts show, and how Meyka AI’s model frames short-term targets and risks.

Pre-market price and volume spike for 6667.HK stock

Mega Genomics (6667.HK) is trading at HK$7.31, a HK$0.35 increase or 5.03% in pre-market trade on 10 Mar 2026. The trade volume is 3,400, far above the 389 average, producing a 73.52x relative volume reading. Such a spike in the Hong Kong (HKSE) pre-market session often indicates institutional or news-driven order flow that can set the tone at the open.

Technical signals: momentum and oversold setup

Price momentum shows a mixed technical picture. The RSI sits at 25.80, an oversold reading that often precedes a bounce, while MACD is negative (MACD -0.05, signal -0.02). ADX at 100.00 points to a strong directional trend, and OBV near 47,400.00 confirms accumulation during earlier moves. Traders watching 6667.HK stock should note the extreme relative volume and the tight intraday range between HK$6.98 and HK$7.31.

Fundamentals snapshot and valuation for 6667.HK stock

Mega Genomics reports an EPS of HK$0.19 and a PE near 36.79 on a market cap of HK$1,567,858,398.00. Key balance metrics show a strong liquidity profile with current ratio 5.84 and cash per share HK$2.45. Price-to-book sits near 2.02, while free cash flow yield is about 9.23%, signaling solid cash generation despite a premium PE versus Healthcare peers. For company details, see the corporate site Mega Genomics and our platform page Meyka stock page.

Meyka AI rates 6667.HK with a score out of 100 and technical analysis

Meyka AI rates 6667.HK with a score out of 100: 68.21 / 100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show oversold short-term conditions with heightened volume, which creates a tradeable setup but not yet a clear directional conviction for buy-side scale-in.

Forecasts, price targets and short-term levels for 6667.HK stock

Meyka AI’s forecast model projects a yearly price of HK$7.43, implying +1.68% versus the current HK$7.31. The model’s monthly figure is HK$6.98 (implied -4.52%) and the quarterly forecast is HK$6.61 (implied -9.55%). Short-term technical targets: resistance HK$7.80, first upside target HK$8.50, and downside support near HK$6.00. Forecasts are model-based projections and not guarantees.

Risks and catalysts affecting 6667.HK stock

Key catalysts include regulatory updates in China’s genetic testing sector, new product approvals, and contract wins with hospitals or health-check centres. Risks include tighter regulation, slower consumer testing demand, and a valuation premium versus the Healthcare sector average PE 27.40, while 6667.HK sits at 36.79. Liquidity is adequate, but earnings surprises and receivables cycles remain monitoring points for investors.

Final Thoughts

The pre-market volume spike in 6667.HK stock on 10 Mar 2026 highlights active interest and a potential short-term trade setup. At HK$7.31 the stock shows an oversold momentum signal (RSI 25.80) alongside a large 73.52x volume surge, which can produce a sharp open-range move. Fundamentals show strong cash per share HK$2.45 and a healthy current ratio 5.84, but valuation is stretched with a PE near 36.79 versus the Healthcare average PE 27.40. Meyka AI’s forecast model projects HK$7.43 for the year, an implied upside of 1.68%, while the monthly projection is HK$6.98 (implied downside -4.52%). Traders looking at 6667.HK stock should weigh the immediate volume-driven momentum against the modest upside from the model and the sector-relative valuation. Use intraday volume confirmation at the open, and consider the stated support HK$6.00 and resistance HK$7.80–HK$8.50 levels when sizing positions. Meyka AI provides this data as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.